Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.

NCT00277875 is registered in ClinicalTrials.gov with Synvista Therapeutics, Inc as lead sponsor.

NCT NCT00277875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00277875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.
Lead sponsor
Synvista Therapeutics, Inc
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2004
Completion date
January 31, 2006
Enrollment
25
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease